Joint Statement on Strengthening the Antibiotic R&D Pipeline by Rewarding Innovation

The emerging threat of antimicrobial resistance (AMR) for public health worldwide is not only
concerning during the COVID-19 pandemic, but will become even more alarming after the current
global health crisis. To combat this threat, no single actor or actor group can deliver a solution
alone. A partnership approach with both the public and private sector is essential to successfully
address the public health impact of AMR. There is a high unmet need for innovative antibiotics that
either overcome resistances and/or offer novel treatment options to yet untargeted pathogens and
to serve the needs of particularly vulnerable populations, especially children and neonates. In addition, for already approved antibiotics the access-to-market transition and their rapid availability and
accessibility in high-burden countries must be much better ensured. Lastly, this goes together with
an appropriate use of antibiotics to avoid the emergence of new resistances (antibiotic stewardship).